---
schema_version: "secwatch.filing_event.v1"
accession: "0000950170-24-091201"
form_type: "8-K"
ticker: "BEAM"
cik: "0001745999"
company_name: "Beam Therapeutics Inc."
filed_at: "2024-08-06T23:59:59+00:00"
generated_at: "2026-05-31T12:21:13.985309+00:00"
event_type: "earnings"
sentiment: "positive"
materiality_score: 0.75
calibrated_materiality_score: 0.75
confidence: "high"
source: SEC EDGAR
---

# Beam Therapeutics Q2 net loss $91.1M; cash $1.0B; BEAM-101 enrollment tops 20, six dosed

## Summary
- Net loss widened to $91.1M ($1.11/shr) from $82.8M ($1.08/shr) in Q2 2023.
- Cash, cash equivalents and marketable securities $1.0B at June 30 vs $1.2B at Dec 31, 2023.
- BEAM-101 Phase 1/2 BEACON trial: >20 patients enrolled, 6 dosed; initial data submitted for ASH.
- FDA cleared IND for BEAM-301 (GSDIa); patient dosing expected in early 2025.
- First patient dosed in BEAM-302 Phase 1/2 trial (AATD); initial clinical data expected in 2025.

## SEC filing metadata
- accession: 0000950170-24-091201
- form_type: 8-K
- ticker: BEAM
- cik: 0001745999
- company_name: Beam Therapeutics Inc.
- filed_at: 2024-08-06T23:59:59+00:00
- event_type: earnings
- sentiment: positive
- materiality_score: 0.75
- calibrated_materiality_score: 0.75
- confidence: high
- sec_items: 2.02, 9.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/1745999/000095017024091201/0000950170-24-091201-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/1745999/000095017024091201/beam-20240806.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0000950170-24-091201
- JSON: https://secwatch.observer/filing/0000950170-24-091201.json
- Plain text: https://secwatch.observer/filing/0000950170-24-091201.txt

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.